Lincoln Pharmaceuticals Share Price

Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the quarter and half year ended on September 30, 2026.

• BSE India
• 4 days 15 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Lincoln Pharmaceuticals announced Q2FY27 results</strong></span></h3> <p><strong _ngcontent-ng-c4151997340="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Revenue from Operations:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 19,134.51 lakh in Q2FY27, registering a QoQ growth of 7.93% from Rs 17,728.21 lakh in Q1FY27 and a YoY growth of 17.13% from Rs 16,336.39 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Other Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Reported at Rs 953.40 lakh in Q2FY27, decreasing 60.71% QoQ from Rs 2,426.46 lakh in Q1FY27 and increasing 31.83% YoY from Rs 723.21 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Total Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Reached Rs 20,087.91 lakh (reported as Rs 200.88 crore in the media release) in Q2FY27, reflecting a minor drop of 0.33% QoQ compared to Rs 20,154.67 lakh in Q1FY27 and an increase of 17.75% YoY compared to Rs 17,059.60 lakh (Rs 170.60 crore) in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">EBITDA:</strong> <ul> <li _ngcontent-ng-c4151997340="">Reported at Rs 33.22 crore in Q2FY27, reflecting a YoY growth of 1.71% compared to Rs 32.66 crore in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Profit Before Tax (PBT):</strong> <ul> <li _ngcontent-ng-c4151997340="">Recorded at Rs 2,901.85 lakh (reported as Rs 29.02 crore in the media release) in Q2FY27, down 38.98% QoQ from Rs 4,755.38 lakh in Q1FY27 and up 0.73% YoY from Rs 2,881.08 lakh (Rs 28.81 crore) in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Net Profit:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 2,042.61 lakh (reported as Rs 20.84 crore in the media release) in Q2FY27, decreasing 43.63% QoQ from Rs 3,623.45 lakh in Q1FY27, but rising 4.15% YoY from Rs 1,998.40 lakh (Rs 20.01 crore) in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Total Comprehensive Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 2,084.48 lakh in Q2FY27 versus Rs 3,665.33 lakh in Q1FY27 and Rs 2,000.69 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Earnings Per Share (EPS):</strong> <ul> <li _ngcontent-ng-c4151997340="">Basic and diluted EPS for Q2FY27 stood at Rs 10.20 per share, compared to Rs 18.09 per share in Q1FY27 and Rs 9.98 per share in Q2FY26 (growth of 2.20% YoY).</li> </ul> </li> </ul> <p><strong _ngcontent-ng-c4151997340="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Revenue from Operations:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 19,134.51 lakh in Q2FY27, up 7.93% QoQ from Rs 17,728.21 lakh in Q1FY27 and up 17.13% YoY from Rs 16,336.39 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Other Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Reached Rs 953.40 lakh in Q2FY27, declining 60.71% QoQ compared to Rs 2,426.46 lakh in Q1FY27, but increasing 31.83% YoY compared to Rs 723.21 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Total Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Recorded at Rs 20,087.91 lakh in Q2FY27, showing a marginal decline of 0.33% QoQ from Rs 20,154.67 lakh in Q1FY27, while rising 17.75% YoY from Rs 17,059.60 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Profit Before Tax (PBT):</strong> <ul> <li _ngcontent-ng-c4151997340="">Reported at Rs 2,901.85 lakh in Q2FY27, down 38.98% QoQ from Rs 4,755.38 lakh in Q1FY27 and up 0.72% YoY from Rs 2,881.08 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Net Profit:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 2,042.61 lakh in Q2FY27, declining 43.63% QoQ compared to Rs 3,623.45 lakh in Q1FY27, but growing 2.21% YoY from Rs 1,998.40 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Total Comprehensive Income:</strong> <ul> <li _ngcontent-ng-c4151997340="">Stood at Rs 2,084.48 lakh in Q2FY27, down 43.13% QoQ from Rs 3,665.33 lakh in Q1FY27 and up 4.19% YoY from Rs 2,000.69 lakh in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Earnings Per Share (EPS):</strong> <ul> <li _ngcontent-ng-c4151997340="">Basic and diluted EPS stood at Rs 10.20 per share in Q2FY27, compared to Rs 18.09 per share in Q1FY27 and Rs 9.98 per share in Q2FY26.</li> </ul> </li> </ul> <p><strong _ngcontent-ng-c4151997340="">Business Highlights & Segment Performance:</strong></p> <ul> <li><strong _ngcontent-ng-c4151997340="">Segment Performance:</strong> <ul> <li _ngcontent-ng-c4151997340="">The company has a single business segment, namely 'Pharmaceutical Business'.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Strategic Revenue Target:</strong> <ul> <li _ngcontent-ng-c4151997340="">The company is targeting revenue of Rs 1,000 crore over the next three years, aiming to achieve an annual growth rate of 15% to 18%, driven by strong performance across key therapeutic segments including cardiac, diabetic, dermatology, and ENT.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Product Portfolio & Expansion:</strong> <ul> <li _ngcontent-ng-c4151997340="">Built on a strong foundation in the acute segment, the company is expanding its portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology.</li> <li _ngcontent-ng-c4151997340="">Introduced four new divisions in the domestic market and added an Active Pharmaceutical Ingredient (API) facility at the Khatraj plant.</li> <li _ngcontent-ng-c4151997340="">Portfolio boasts over 1,700 registered products, with 700 more in development/pipeline, spanning 600 plus formulations in 15 therapeutic areas (including anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria).</li> <li _ngcontent-ng-c4151997340="">The company has filed 25 plus patent applications and holds seven patents.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Global Footprint:</strong> <ul> <li _ngcontent-ng-c4151997340="">Currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia.</li> <li _ngcontent-ng-c4151997340="">Plans to expand this footprint to 90 countries over the next 2 to 3 years, backed by recent entry into the Canadian market and regulatory approvals from TGA (Australia) and EU GMP.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Manufacturing & Distribution:</strong> <ul> <li _ngcontent-ng-c4151997340="">Operates two manufacturing facilities at Khatraj (Ahmedabad) and Mehsana, Gujarat, with international certifications including EUGMP, TGA, WHO-GMP, ISO-9001:2015, ISO-14001:2015, and ISO-45001:2018.</li> <li _ngcontent-ng-c4151997340="">Domestic distribution includes a field force of over 600 with 21+ Super Stockists covering 26 states across India.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Debt and Shareholding:</strong> <ul> <li _ngcontent-ng-c4151997340="">The company remains net-debt free with strong liquidity.</li> <li _ngcontent-ng-c4151997340="">FII holding in the company stood at 4.55% as of September 30, 2026.</li> </ul> </li> <li _ngcontent-ng-c4151997340=""><strong _ngcontent-ng-c4151997340="">Dividend:</strong> <ul> <li _ngcontent-ng-c4151997340="">Shareholders approved a dividend of Rs 1.80 per share (18%) for FY26 at the 32nd Annual General Meeting held on September 30, 2026.</li> </ul> </li> </ul> <p><strong _ngcontent-ng-c4151997340="">Munjal Patel, Director, Lincoln Pharmaceuticals said,</strong> "We are pleased to report another strong quarter, reflecting our focus on sustainable growth and long-term value creation. During FY26, we expanded our domestic presence with the launch of four new divisions, strengthened our manufacturing capabilities through the Khatraj plant expansion and the addition of a new API facility. In FY27, we will continue to evaluate opportunities to expand our presence across domestic and international markets, leveraging our enhanced manufacturing capabilities and robust product pipeline.</p> <p _ngcontent-ng-c4151997340="">With consistent performance across business verticals and a continued focus on maintaining a debt-free balance sheet, we remain committed to driving sustainable, profitable growth and delivering long-term shareholder value through disciplined execution of our strategic initiatives."</p> <p><a class="lb" href="/get-document/post/pdf/5916182/" target="_blank">Result PDF</a></p>

• Trendlyne
• 5 days 13 hours ago

Un-Audited Financial Results For the Quarter and Half year Ended on September 30 ,2026.

• BSE India
• 5 days 14 hours ago